Skip to main content
Erschienen in: PharmacoEconomics 1/2005

01.01.2005 | Practical Application

Measuring productivity changes in economic evaluation

Setting the research agenda

verfasst von: Dr Marc Koopmanschap, Alex Burdorf, Karin Jacob, Willem Jan Meerding, Werner Brouwer, Hans Severens

Erschienen in: PharmacoEconomics | Ausgabe 1/2005

Einloggen, um Zugang zu erhalten

Abstract

Productivity costs related to illness may be relevant in assessing healthcare programmes for patients, as well as occupational interventions for workers. When performing an economic evaluation for both types of programmes, a sound methodology for measuring and valuing these productivity costs is essential. This article reviews research questions related to productivity and health, focusing on the costs of short-term absence from work, productivity costs without absence (‘presenteeism’) and possible compensation mechanisms and circumstances that may affect productivity costs. Furthermore, the important but under-explored relationship between productivity and QOL is analysed.
Strategies for better answers on these research questions, such as developing more valid measurement instruments, are discussed. It is stressed that the analysis of productivity costs should not be restricted to the level of the individual patient and worker but extended to the level of teams of workers and firms. It may be advisable to explore several issues such as compensation mechanisms and efficiency losses in detail using employee questionnaires and consecutively applying the key elements in patient settings. It seems advisable to develop flexible, modular instruments for measuring and valuing absence from work, compensation mechanisms, efficiency loss and details of jobs and organisation in an integrative and consistent way. Further, it seems crucial to identify what determinants of jobs and organisations are the key factors in estimating productivity costs. This list of determinants could be mapped with a classification of jobs, to be used as a screener in patient questionnaires.
Literatur
1.
Zurück zum Zitat Ten years of working conditions in the European Union. Dublin: European Foundation, 2001 Ten years of working conditions in the European Union. Dublin: European Foundation, 2001
2.
Zurück zum Zitat Brouwer WBF, Schut FT. Priority care for employees: a blessing in disguise? Health Econ 1999 Feb; 8 (1): 65–73CrossRef Brouwer WBF, Schut FT. Priority care for employees: a blessing in disguise? Health Econ 1999 Feb; 8 (1): 65–73CrossRef
3.
Zurück zum Zitat Guidelines for economic evaluation of pharmaceuticals. 2nd ed. Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1997 Guidelines for economic evaluation of pharmaceuticals. 2nd ed. Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1997
4.
Zurück zum Zitat Guidelines for the pharmaceutical industry on preparation of submission to the pharmaceutical Benefits Advisory Committee. Canberra: Commonwealth Department of Human Services, 1995 Guidelines for the pharmaceutical industry on preparation of submission to the pharmaceutical Benefits Advisory Committee. Canberra: Commonwealth Department of Human Services, 1995
5.
Zurück zum Zitat Riteco JA, De Heij LJM, van Luijn JCF, et al. Dutch guidelines: pharmacoeconomic research guidelines. Amstelveen: CvZ, 1999 Riteco JA, De Heij LJM, van Luijn JCF, et al. Dutch guidelines: pharmacoeconomic research guidelines. Amstelveen: CvZ, 1999
6.
Zurück zum Zitat Johanneson M, Meltzer D. Some reflections on cost-effectiveness analysis. Health Econ 1998 Feb; 7 (1): 1–7CrossRef Johanneson M, Meltzer D. Some reflections on cost-effectiveness analysis. Health Econ 1998 Feb; 7 (1): 1–7CrossRef
7.
Zurück zum Zitat Koopmanschap MA, Rutten FFH, van Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 15: 171–89CrossRef Koopmanschap MA, Rutten FFH, van Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 15: 171–89CrossRef
8.
Zurück zum Zitat Koopmanschap MA, van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med 1992; 34 (9): 1005–10CrossRef Koopmanschap MA, van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med 1992; 34 (9): 1005–10CrossRef
9.
Zurück zum Zitat Borghouts JAJ, Koes BW, Vondeling H, et al. Cost-of-illness of neck pain in The Netherlands in 1996. Pain 1999; 80: 629–36CrossRef Borghouts JAJ, Koes BW, Vondeling H, et al. Cost-of-illness of neck pain in The Netherlands in 1996. Pain 1999; 80: 629–36CrossRef
10.
Zurück zum Zitat Maniadakis N, Gray A. The economic burden of back pain in the UK. Pain 2000; 84: 95–103CrossRef Maniadakis N, Gray A. The economic burden of back pain in the UK. Pain 2000; 84: 95–103CrossRef
11.
Zurück zum Zitat Boonen A, van der Heijde D, Landewe R, et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 2002; 61: 429–37CrossRef Boonen A, van der Heijde D, Landewe R, et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 2002; 61: 429–37CrossRef
12.
Zurück zum Zitat Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996 Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996
13.
Zurück zum Zitat Brouwer WBF, Koopmanschap MA, Rutten FFIL Productivity costs measurement through QOL? A response to the recommendation of the Washington panel. Health Econ 1997; 6: 253–9CrossRef Brouwer WBF, Koopmanschap MA, Rutten FFIL Productivity costs measurement through QOL? A response to the recommendation of the Washington panel. Health Econ 1997; 6: 253–9CrossRef
14.
Zurück zum Zitat Brouwer WBF, Koopmanschap MA, Rutten FFIL Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion. Health Econ 1997; 6: 511–4CrossRef Brouwer WBF, Koopmanschap MA, Rutten FFIL Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion. Health Econ 1997; 6: 511–4CrossRef
15.
Zurück zum Zitat Pauly MV, Nicholson S, Xu J, et al. A general model of the impact of absenteeism on employers and employees. Health Econ 2002; 11: 221–31CrossRef Pauly MV, Nicholson S, Xu J, et al. A general model of the impact of absenteeism on employers and employees. Health Econ 2002; 11: 221–31CrossRef
16.
Zurück zum Zitat Sculpher M. The role and estimation of productivity costs in economic evaluation. In: Drummond MF, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press, 2001 Sculpher M. The role and estimation of productivity costs in economic evaluation. In: Drummond MF, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press, 2001
17.
Zurück zum Zitat Severens JL, Laheij RJF, Jansen JBMJ, et al. Estimating the cost of lost productivity in dyspepsia. Aliment Pharmacol Ther 1998; 12: 919–23CrossRef Severens JL, Laheij RJF, Jansen JBMJ, et al. Estimating the cost of lost productivity in dyspepsia. Aliment Pharmacol Ther 1998; 12: 919–23CrossRef
18.
Zurück zum Zitat Brouwer WBF, Koopmanschap MA, Rutten FFIL Productivity costs before and after absence from work: as important as common? Health Policy 2002; 61: 173–87CrossRef Brouwer WBF, Koopmanschap MA, Rutten FFIL Productivity costs before and after absence from work: as important as common? Health Policy 2002; 61: 173–87CrossRef
19.
Zurück zum Zitat Brouwer WBF, Koopmanschap MA, Rutten FFIL Productivity losses without absence: measurement validation and empirical evidence. Health Policy 1999; 48: 13–27CrossRef Brouwer WBF, Koopmanschap MA, Rutten FFIL Productivity losses without absence: measurement validation and empirical evidence. Health Policy 1999; 48: 13–27CrossRef
20.
Zurück zum Zitat Van Roijen L, Essink-Bot ML, Koopmanschap MA, et al. Labour and health status in economic evaluation of health care: the health and labour questionnaire. Int J Technol Assess Health Care 1996; 12: 405–15CrossRef Van Roijen L, Essink-Bot ML, Koopmanschap MA, et al. Labour and health status in economic evaluation of health care: the health and labour questionnaire. Int J Technol Assess Health Care 1996; 12: 405–15CrossRef
21.
Zurück zum Zitat Hagberg M, Wigaeus-Torngvist E, Toomingas A. Self-report reduced productivity due to musculoskeletal symptoms: associations with workplace and individual factors among whitecollar computer users. J Occup Rehabil 2002; 12: 151–62CrossRef Hagberg M, Wigaeus-Torngvist E, Toomingas A. Self-report reduced productivity due to musculoskeletal symptoms: associations with workplace and individual factors among whitecollar computer users. J Occup Rehabil 2002; 12: 151–62CrossRef
22.
Zurück zum Zitat Brouwer WBF, Koopmanschap MA. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998; 13 (5 Pt 1): 563–9CrossRef Brouwer WBF, Koopmanschap MA. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998; 13 (5 Pt 1): 563–9CrossRef
23.
Zurück zum Zitat Berger ML, Murray JF, Xu J, et al. Alternative valuations of work loss and productivity. J Occup Environ Med 2001; 43 (1): 18–24CrossRef Berger ML, Murray JF, Xu J, et al. Alternative valuations of work loss and productivity. J Occup Environ Med 2001; 43 (1): 18–24CrossRef
24.
Zurück zum Zitat Severens JL, Mulder J, Laheij RJF, et al. Precision and accuracy in measuring absence from work as a basis for calculating productivity costs in The Netherlands. Soc Sci Med 2000; 51: 243–9CrossRef Severens JL, Mulder J, Laheij RJF, et al. Precision and accuracy in measuring absence from work as a basis for calculating productivity costs in The Netherlands. Soc Sci Med 2000; 51: 243–9CrossRef
25.
Zurück zum Zitat Severens JL, Mulder J, Laheij RJF, et al. Validity of measuring compensation mechanisms for absence from work as a basis for calculating productivity costs. 15th Annual International Society of Technology Assessment in Healthcare (ISTAHC) Meeting; June 1999, Edinburgh Severens JL, Mulder J, Laheij RJF, et al. Validity of measuring compensation mechanisms for absence from work as a basis for calculating productivity costs. 15th Annual International Society of Technology Assessment in Healthcare (ISTAHC) Meeting; June 1999, Edinburgh
26.
Zurück zum Zitat Koopmanschap MA, Rutten FFIL van Ineveld BM, et al. Reply to Johannesson’s and Karlsson’s comment. J Health Econ 1997; 16: 257–9CrossRef Koopmanschap MA, Rutten FFIL van Ineveld BM, et al. Reply to Johannesson’s and Karlsson’s comment. J Health Econ 1997; 16: 257–9CrossRef
27.
Zurück zum Zitat Lamers LM, Meerding WY, Severen JL et al. The relationship between productivity and health related QOL: a empirical exploration in persons with low back pain. QOL Research. In press Lamers LM, Meerding WY, Severen JL et al. The relationship between productivity and health related QOL: a empirical exploration in persons with low back pain. QOL Research. In press
28.
Zurück zum Zitat Osterhaus IT, Gutterman DL, Plachetka JR. Health care resource and lost labour costs of migraine headache in the US. Pharmacoeconomics 1992; 2: 67–76CrossRef Osterhaus IT, Gutterman DL, Plachetka JR. Health care resource and lost labour costs of migraine headache in the US. Pharmacoeconomics 1992; 2: 67–76CrossRef
29.
Zurück zum Zitat Lerner D, Amick BC, Rogers WH, et al. The work limitations questionnaire. Med Care 2001; 39 (1): 72–85CrossRef Lerner D, Amick BC, Rogers WH, et al. The work limitations questionnaire. Med Care 2001; 39 (1): 72–85CrossRef
Metadaten
Titel
Measuring productivity changes in economic evaluation
Setting the research agenda
verfasst von
Dr Marc Koopmanschap
Alex Burdorf
Karin Jacob
Willem Jan Meerding
Werner Brouwer
Hans Severens
Publikationsdatum
01.01.2005
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 1/2005
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200523010-00004

Weitere Artikel der Ausgabe 1/2005

PharmacoEconomics 1/2005 Zur Ausgabe